246 related articles for article (PubMed ID: 37631344)
1. Targeting EGFR/PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma.
Bang J; Jun M; Lee S; Moon H; Ro SW
Pharmaceutics; 2023 Aug; 15(8):. PubMed ID: 37631344
[TBL] [Abstract][Full Text] [Related]
2. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
3. A selective androgen receptor modulator, S4, displays robust anti-cancer activity on hepatocellular cancer cells by negatively regulating PI3K/AKT/mTOR signalling pathway.
Yavuz M; Takanlou LS; Avcı ÇB; Demircan T
Gene; 2023 Jun; 869():147390. PubMed ID: 36990257
[TBL] [Abstract][Full Text] [Related]
4. BEZ235 increases sorafenib inhibition of hepatocellular carcinoma cells by suppressing the PI3K/AKT/mTOR pathway.
Li A; Zhang R; Zhang Y; Liu X; Wang R; Liu J; Liu X; Xie Y; Cao W; Xu R; Ma Y; Cai W; Wu B; Cai S; Tang X
Am J Transl Res; 2019; 11(9):5573-5585. PubMed ID: 31632530
[TBL] [Abstract][Full Text] [Related]
5. DHW-208, A Novel Phosphatidylinositol 3-Kinase (PI3K) Inhibitor, Has Anti-Hepatocellular Carcinoma Activity Through Promoting Apoptosis and Inhibiting Angiogenesis.
Wang S; Wu Y; Liu M; Zhao Q; Jian L
Front Oncol; 2022; 12():955729. PubMed ID: 35903690
[TBL] [Abstract][Full Text] [Related]
6. Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Cui SX; Shi WN; Song ZY; Wang SQ; Yu XF; Gao ZH; Qu XJ
Oncotarget; 2016 Jun; 7(24):36767-36782. PubMed ID: 27167344
[TBL] [Abstract][Full Text] [Related]
7. Catalpol synergistically potentiates the anti-tumour effects of regorafenib against hepatocellular carcinoma via dual inhibition of PI3K/Akt/mTOR/NF-κB and VEGF/VEGFR2 signaling pathways.
El-Hanboshy SM; Helmy MW; Abd-Alhaseeb MM
Mol Biol Rep; 2021 Nov; 48(11):7233-7242. PubMed ID: 34596810
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
Zhou Q; Lui VW; Yeo W
Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
[TBL] [Abstract][Full Text] [Related]
9. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
[TBL] [Abstract][Full Text] [Related]
10. Xihuang pills induce apoptosis in hepatocellular carcinoma by suppressing phosphoinositide 3-kinase/protein kinase-B/mechanistic target of rapamycin pathway.
Teng YJ; Deng Z; Ouyang ZG; Zhou Q; Mei S; Fan XX; Wu YR; Long HP; Fang LY; Yin DL; Zhang BY; Guo YM; Zhu WH; Huang Z; Zheng P; Ning DM; Tian XF
World J Gastrointest Oncol; 2022 Apr; 14(4):872-886. PubMed ID: 35582102
[TBL] [Abstract][Full Text] [Related]
11. Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma.
Kim MN; Lee SM; Kim JS; Hwang SG
Cancer Chemother Pharmacol; 2019 Oct; 84(4):809-817. PubMed ID: 31385002
[TBL] [Abstract][Full Text] [Related]
12. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
Beck JT; Ismail A; Tolomeo C
Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
[TBL] [Abstract][Full Text] [Related]
13. Sphingosine 1-phosphate receptor 2 promotes the onset and progression of non-alcoholic fatty liver disease-related hepatocellular carcinoma through the PI3K/AKT/mTOR pathway.
Wang G; Zhang X; Zhou Z; Song C; Jin W; Zhang H; Wu W; Yi Y; Cui H; Zhang P; Liu X; Xu W; Shen X; Shen W; Wang X
Discov Oncol; 2023 Jan; 14(1):4. PubMed ID: 36631680
[TBL] [Abstract][Full Text] [Related]
14. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
Yu L; Wei J; Liu P
Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
[TBL] [Abstract][Full Text] [Related]
15. PI3K/AKT/mTOR pathway-related long non-coding RNAs: roles and mechanisms in hepatocellular carcinoma.
Wu Y; Zhang Y; Qin X; Geng H; Zuo D; Zhao Q
Pharmacol Res; 2020 Oct; 160():105195. PubMed ID: 32916254
[TBL] [Abstract][Full Text] [Related]
16. Vertical Targeting of AKT and mTOR as Well as Dual Targeting of AKT and MEK Signaling Is Synergistic in Hepatocellular Carcinoma.
Ewald F; Nörz D; Grottke A; Bach J; Herzberger C; Hofmann BT; Nashan B; Jücker M
J Cancer; 2015; 6(12):1195-205. PubMed ID: 26535060
[TBL] [Abstract][Full Text] [Related]
17. BEZ235 enhances chemosensitivity of paclitaxel in hepatocellular carcinoma through inhibiting the PI3K/Akt/mTOR pathway.
Liu X; Xie C; Li A; Zhang Y; Liu X; Zhou S; Shen J; Huo Z; Cao W; Ma Y; Xu R; Xing Y; Xie Y; Cai S; Tang X
Am J Transl Res; 2019; 11(12):7255-7271. PubMed ID: 31934276
[TBL] [Abstract][Full Text] [Related]
18. SOCS5 inhibition induces autophagy to impair metastasis in hepatocellular carcinoma cells via the PI3K/Akt/mTOR pathway.
Zhang M; Liu S; Chua MS; Li H; Luo D; Wang S; Zhang S; Han B; Sun C
Cell Death Dis; 2019 Aug; 10(8):612. PubMed ID: 31406106
[TBL] [Abstract][Full Text] [Related]
19. Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma.
Narayanankutty A
Curr Mol Pharmacol; 2021; 14(5):760-769. PubMed ID: 33494690
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of microRNA-133b is associated with the increased survival of patients with hepatocellular carcinoma after curative hepatectomy: Involvement of the EGFR/PI3K/Akt/mTOR signaling pathway.
Wang X; Zeng J; Wang L; Zhang X; Liu Z; Zhang H; Dong J
Oncol Rep; 2017 Jul; 38(1):141-150. PubMed ID: 28586051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
